The role of neutrophil extracellular traps in acute lung injury

1ALI is an inflammatory condition characterized by the acute onset of lung tissue damage and pulmonary dysfunction originating from infectious or sterile insults. Typical features of ALI are the alveolar accumulation of protein-rich fluid and activated immune cells due to pulmonary endothelial barrier disruption and increased vascular permeability. The pathological alterations of ALI are responsible for a clinical syndrome characterized by extensive non-cardiogenic pulmonary edema and decreasing oxygenation, also known as acute respiratory distress syndrome (ARDS). ARDS is associated with high morbidity and mortality (~40%), and its increasing incidence, particularly related to the recent COVID-19 pandemic, represents a significant global burden.

2Airway neutrophilia has been historically considered a hallmark of ARDS. However, the underlying mechanisms that control neutrophil contribution to ALI are not fully understood. Although neutrophils play well-established functions in regulating pulmonary injury through the generation of reactive oxygen species (ROS) or conducting phagocytosis and degranulation, recent reports have highlighted a critical role for NETosis in ALI pathogenesis. NETs consist of a mix of nuclear chromatin, mitochondrial DNA and neutrophil granule proteins that primarily absolve a defensive role against lung infections. On the other hand, accumulating evidence indicate that NETosis is also increased in lung sterile inflammatory conditions and that exuberant NET release promotes microvascular dysfunction, thromboinflammation, and direct cellular injury. Moreover, high levels of NETs in the peripheral blood or bronchoalveolar lavage (BAL) of critically ill subjects are frequently associated with the worst ARDS outcomes.

3In this review, we will discuss general mechanisms of NETosis and NET-mediated tissue damage ( Figure 1 ) with a specific focus on the contribution of NETs to different forms of infective and sterile ALI ( Figure 2 ).

4NETosis was first described in 2004 when Brinkman and coworkers observed that activated neutrophils could kill bacteria by releasing nuclear chromatin decorated with proteins usually confined to their granules. Following studies characterized the NADPH oxidase 2 (NOX2) Ros-dependent pathway involved in the release of NETs and defined NETosis as a new mechanism of neutrophil programmed cell death distinct from apoptosis and necrosis. NETosis was originally described as a slow multistep process that leads directly to senescence, where chromatin decondensation and nuclear envelope rupture allow for mixing nuclear material with cytoplasm content. Pore-forming proteins like gasdermin D then permeabilize the plasma membrane allowing for the release of NETs into the extracellular space. However, this view of NETosis as a terminal process has been recently challenged by the demonstration of an alternative, non-lytic and NADPH-independent mechanism of NET release, which appears to be particularly rapid in response to bacterial infection and leaves behind a neutrophil that can still exclude vital dyes. This form of NETosis is initiated by a sudden rise in intracellular calcium that leads to the expulsion of nuclear chromatin and granule proteins, resulting in an anucleated cytoplast still capable of migration and phagocytosis. Finally, a third type of fast, vital and ROS-dependent NETosis was recently described in response to granulocyte-macrophage colony-stimulating factor or lipopolysaccharide (LPS) leading to the release of mitochondrial DNA (mtDNA) mixed with granule proteins.

5Almost two decades after the first observations, it is now commonly accepted that NET release can occur in response to multiple stimuli via several and frequently interconnected activation pathways that are not necessarily associated with neutrophil death. Regardless of the stimuli and the activation mechanisms, NET composition has intrinsic pro-inflammatory characteristics due to the presence of granule-derived proteases, histones and cell-free DNA.

6Under homeostatic conditions, neutrophil azurophilic granules contain different serine proteases, including neutrophil elastase (NE), cathepsin G (CatG), proteinase 3 (PR3), and neutrophil serine protease 4 (NSP4). Due to their antimicrobial and immunomodulatory function, these pre-stored catalytically active mediators play a major contribution in the physiological response to infection. However, their uncontrolled extracellular release may have unintended consequences by causing damage to the surrounding healthy tissue. Proteomic analysis and studies on the functional activity of human NETs indicate that NE is the most abundant non-histone protein and the predominant responsible for the NET “proteolytic signature”. NE is a well-established mediator of alveolo-capillary permeability where it is thought to trigger microvascular injury through primarily catalyzing endothelial cell cadherin proteolysis. In a mouse model of LPS induced endotoxemia, treatment with the NE selective inhibitor Sivelestat attenuated pulmonary endothelial injury reducing endothelial glycocalyx damage and preserving thrombomodulin and syndecan-1 expression. Similar findings were observed in work by Okeke and colleagues, where Sivelestat treatment reduced NET-mediated injury on human umbilical vein endothelial cells (HUVECs). Interestingly, Sivelestat was able to reverse the NET-mediated upregulation of Intercellular Adhesion Molecule-1 (ICAM-1) on HUVECs, suggesting that NETs may propagate the inflammatory response of endothelial cells through NE. Furthermore, reduced NET deposition after Sivelestat treatment also suggested that NE may be directly involved in the release of NETs. This observation would be consistent with previous findings describing the role of NE nuclear translocation in facilitating histone degradation and chromatin decondensation. However, in mice genetically deficient for NE, the stimulation with the well-known NETosis inducer, phorbol 12-myristate 13-acetate (PMA), does not abrogate the release of NETs. In addition, the effect of NE inhibition appears to vary among neutrophils from different healthy donors, suggesting that NE may not always be necessary for the execution of NETosis.

7Other proteases such as PR3 and Cat G are known to enhance inflammatory reactions by modulating the balance between pro and anti-inflammatory proteins. However, despite their documented proteolytic activity in human NETs, the precise contribution to mediating ALI is currently less clear.

8In summary, besides the explicit role of NE in NET-mediated lung microvascular damage, the overall contribution of neutrophil serine proteases to NET-dependent inflammation in ALI is still undefined.

9Histones are generally located within the cell nucleus, where they play an essential role in organizing and regulating DNA. During NETosis, the enzyme peptidyl arginine deiminase 4 (PAD4) alters histone intermolecular interactions by converting arginine residues into citrulline. Citrullination decreases histone protein stability and facilitates chromatin decondensation and chromosomal DNA expulsion. PAD4-dependent histones citrullination has been frequently reported as a critical component of NETosis in response to numerous physiological stimuli, and treatment with PAD4 inhibitors such as Cl-amidine and GSK484 have been shown positive effects in attenuating ALI. Interestingly, recent works indicate that there are conditions where NETosis can occur even in the absence of PAD4 activity, for example, in response to Candida albicans, Klebsiella pneumoniae or cholesterol crystals. These evidence suggest that during NETosis, chromatin decondensation may be not exclusively dependent on histone citrullination and that alternative mechanisms, such as direct histone cleavage by NE nuclear translocation, may also be involved. How different NET stimuli activate alternative mechanisms of chromatin decondensation and what is the level of redundancy and interaction between such pathways remains unclear, indicating the need for a better characterization of the upstream signaling involved in NET formation and release.

10Extracellular histones account for ~70% of all NET-associated proteins, and their presence highly contributes to NET-mediated thromboinflammation. For example, histone engagement of TLR2 and TLR4 can induce platelet activation resulting in the release of thrombin. In addition, histones can activate αIIbβ3 integrin on the platelet surface, inducing subsequent fibrinogen-mediated platelet aggregation. Histones also appear to stimulate TLR9-dependent responses leading to mitochondrial ROS production and NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome activation. In a mouse model of ALI secondary to severe trauma, high circulating histones were associated with signs of edema, increased alveolar wall thickening, and occasional hemorrhage. However, inhibition with TLR4 and TLR2-neutralizing antibodies did not show protective effects on cultured endothelial cells suggesting that TLR activation may not be the major pathway for histone toxicity. In this regard, extracellular histones have been shown to cause endothelial cell damage through direct interactions with the plasma membrane phospholipids, which lead to increased transmembrane conductance. Although DNase treatment is generally considered effective in degrading NET DNA scaffold, questions remain on the fate of NET proteins, particularly histones, after DNase digestion. For example, Saffarzadeh and coworkers show that DNase-mediated NET degradation was insufficient to abolish NET cytotoxicity, suggesting that histone proteins, after DNA digestion, can still mediate most of the NET-related tissue damage. Similar findings are also present in work by Kolaczkowska and colleagues where, in a model of bloodstream infection with methicillin-resistant Staphylococcus aureus (MRSA), they demonstrate that significant amount of active histones and NE remained attached to the vasculature wall after DNase treatment.

11In summary, extracellular histones play a potent and heterogeneous contribution in NET-mediated thromboinflammation and tissue injury. Reducing the release, neutralizing, or blocking histone signal transduction may represent in the future a novel pharmacological approach for ALI treatment.

12DNA forms the NET backbone, and for a long time, its singular function has been thought limited to maintaining NET structural integrity. However, recent findings suggest that DNA may also play a direct role in promoting thromboinflammation. Besides providing a scaffold for the recruitment of platelets, leukocytes, and coagulation factors, cell-free DNA derived from NETs has been shown to mediate thrombin generation through the Factor XII- or Factor XI-dependent coagulation pathways in patients with sepsis. Accordingly, the digestion or precipitation of DNA networks markedly diminishes NET pro-coagulant effects. In addition to nuclear DNA, NETs can also be enriched with DNA derived from mitochondria (mtDNA). mtDNA are circular molecules of double-stranded DNA that encode for some of the genes that form the electron transport chain as well as drive mitochondrial-specific protein synthesis. However, given their ancient bacterial origin, NET-associated mtDNA release can act as a damaged associated molecular pattern (DAMP) by stimulating the CpG DNA sensor TLR9 as well as triggering NLRP3 inflammasome pathway activation on immune cells. In addition, the NET-mediated release of oxidized mtDNA has been shown to stimulate type I interferon (IFN) signaling through a signaling pathway dependent on the DNA sensor stimulator of interferon genes (STING), an intracellular pattern recognition receptor. Moreover, recent findings indicate that mtDNA can also directly activate neutrophils to release NETs through TLR9 engagement.

13In summary, besides acting as a scaffold, NET DNA may directly stimulate innate immune responses that promote pulmonary inflammation.

14Sepsis is a common and deadly inflammatory condition defined as a dysregulated host response to infection associated with multi-organ dysfunction. With the development of ARDS, lung involvement is frequently observed in critically ill subjects affected with sepsis. Moreover, infectious pneumonia is one of the leading causes of sepsis and the most frequent cause of ALI. Although pathogens themselves can directly damage the lung, a significant contribution to the injury comes from the exuberant activation of the host immune cells in response to pathogen-associated molecular patterns (PAMPs) and DAMPs, collectively defined as “alarmins”.

15NETs have been firstly described as a potent defensive mechanism able to block and inactivate pathogens preventing their growth and dissemination. The cationic NETs components provide an ideal scaffold for electrostatic interactions with the negatively charged surface of microorganisms exposing them to a high local concentration of cytotoxic molecules. Moreover, even in the absence of direct killing, experiments in primary human neutrophils showed that NETs can indirectly increase the complement ability to destroy pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. Considering the major role played by NETs in controlling infections, it is not surprising that several microbes have evolved specific adaptive strategies to counteract this defensive mechanism. For example, Streptococcus pneumoniae, the most common cause of community-acquired pneumonia (CAP), expresses endonucleases that degrade the NET DNA scaffold allowing for bacterial escape. In alternative, Bordetella pertussis, the causative agent of whooping cough, expresses adenylate cyclase toxin (ACT) which inhibits the release of NETs by increasing cAMP levels and reducing intracellular ROS production. In humans, the critical role of NETs in protecting from lung infections is evident in subjects affected by Chronic Granulomatous Disease (CDG), a systemic disorder caused by a genetic deficiency in NADPH oxidase and consequent impairment in NET formation. Initially described as “a fatal granulomatous disease of childhood’’, CGD used to be associated with recurrent respiratory infections and high mortality rate before the introduction of effective antimicrobial treatments. The protective role of NETs, particularly in the early phase of infection, in controlling pathogen growth and dissemination is also evident from experimental observations. In a mouse model of polymicrobial sepsis by cecal ligation puncture (CLP), Czaikoski and coworkers report that DNase treatment increased systemic bacterial burden and decreased survival. Consistent results were also reported by Meng and coworkers that, using DNase treatment in a similar mouse model of sepsis, described a profound and sustainable reduction of NET-mediated bactericidal activity associated with worst inflammation, more severe organ injury and higher early mortality. Finally, better outcomes in sepsis were reported by Lee and coworkers in mice deficient for phospholipase D2 (PLD2) that exhibit an intrinsic up-regulation of PAD4 activity associated with augmenting NET formation and bacterial killing.

16Although the contribution of NETs in pathogen clearance is well established, aberrant NET release, particularly into the lung, has also been associated with the exacerbation of inflammation, immunothrombosis, and tissue injury. For example, NETs formed during LPS-induced ALI have been shown to directly cause organ damage and exacerbate an inflammatory response characterized by leukocyte accumulation, diffuse alveolar damage and cytokine release which could be improved by DNase treatment. Further details into the mechanism of NeT-mediated damage during bacterial sepsis were provided by McDonald and coworkers that recently described the implication of NET–platelet–thrombin axis in the promotion of intravascular coagulation and showed that PAD4 deficient mice or mice that received DNase have reduced microvascular occlusion and organ dysfunction. Blocking NET release by pharmacological inhibition of Gasdermin D or PAD4 similarly reduced signs of sepsis-related multi-organ dysfunction and ALI. Moreover, data on critically ill subjects affected with infectious pneumonia and sepsis indicate that higher circulating NETs are associated with the worst clinical outcomes and directly correlate with organ dysfunction. Finally, a meta-analysis of randomized controlled trials on the use of Sivelestat for the treatment of ARDS in subjects with sepsis showed improved lung function even in the absence of a significant increased overall survival.

17A possible explanation for the complex interplay between antimicrobial and pro-inflammatory NET function has been recently proposed by Lafrançais and coworkers. In this study, the authors confirmed the presence of higher levels of NETs in ARDS subjects with infectious etiology that correlated with the worst clinical outcomes. Moreover, in a mouse model of bacterial pneumonia, they found that NET release exacerbated signs of ALI, which could be attenuated in PAD4 deficient mice or by DNase administration. Interestingly, increased bacterial growth, particularly observed in mice with a genetic defect in NETosis, partially counteracted these beneficial effects, suggesting that the early release of NETs is important in initially control the infection and that ARDS in sepsis may represent the maladaptive consequence of this primarily defense mechanism. This view is consistent with previous findings showing that early DNase administration in a CLP model of sepsis increased signs of ALI but that the same treatment delivered in later phases was beneficial in reducing the level of systemic inflammation and increased survival.

18In conclusion, the experimental evidence summarized in Table 1, and the clinical observations from sepsis subjects with ARDS, indicate that NETs play a dual role in ALI associated with sepsis and pneumonia. On the one hand, the early release of NETs at the site of infection is essential for controlling pathogen growth, and defects in NETosis or early NET degradation are associated with recurrent pneumonia and disseminated infections. However, NET exuberant release, particularly in a later phase dominated by post-infectious inflammatory events, appears largely detrimental and concurrently exacerbates tissue damage and ALI. Possible therapeutic strategies directed to modulate NET-mediated lung damage during infection should consider this dynamic relation between the early contribution to pathogen control and the late post-infectious exacerbation of systemic inflammation.

19COVID-19 is a global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, which in its most severe clinical presentation, is associated with ALI/ARDS and multiple organ failure. COVID-19 infection with a high neutrophil-to-lymphocyte ratio is generally associated with the worst clinical outcomes. Neutrophil activation signature is a prominent feature of circulating leukocyte transcriptomes of severe cases. Additionally, single-cell RNA sequencing (scRNA-seq) analysis of COVID-19 whole blood samples has revealed distinct neutrophil clusters associated with NET release and disease severity. In order to characterize COVID-19 immunopathogenesis, several studies have focused on neutrophil effector functions, and in particular, NETosis. SARS-CoV-2 infection has been shown to directly induce NETosis in healthy neutrophils. NETosis has also been reported as a predictor of COVID-19 severity. Post-mortem examinations of lungs from COVID-19 patients reveal diffuse neutrophil infiltration with abundant NET deposition frequently associated with platelet accumulation and microvascular thrombosis. This inflammatory pattern of thrombosis is consistent with findings from Zuo and colleagues, who showed a positive correlation between markedly elevated cell-free DNA and D-dimer levels, a degradation product of fibrin. The pathogenic role of NET release has also been described in different thrombosis-mediated inflammatory states associated with ARDS. One current view of the underlying causes of ALI-mediated pulmonary thrombosis is that NET web-like structures immobilize and activate platelets and leukocytes. Through mechanisms that have yet to be fully elucidated, this induces a feed-forward loop that triggers additional intravascular NETosis and higher local concentrations of histones and proteases that increase endothelial permeability and promote microvascular obstruction. Given the prominent role of immunothrombosis in the pathogenesis of COVID-19 ALI/ARDS, pharmacological NET inhibition or degradation could represent an intriguing approach to attenuate disease severity and improve survival. A recent study by Fisher and colleagues supports this notion by showing remarkable improvement in clinical outcomes in five severely ill COVID-19 subjects treated with off-label aerosolized recombinant human (rh) DNase. Similar findings were also observed in different single-center case series and cohort studies where nebulized rhDNase administration showed favorable clinical outcomes in the absence of drug-associated toxicities. Although the results from these small observational studies are encouraging, larger and randomized clinical trials will be required to assess the long terms effects of DNase treatment on COVID-19 ARDS.

20TRALI is a form of ALI that occurs within six hours of transfusion that cannot be explained by another ALI risk factor. Neutrophil activation and sequestration within the pulmonary capillaries in response to blood components is considered a central feature in the pathogenesis of TRALI. Recent insights into the mechanisms of neutrophil-mediated tissue damage indicate that NETs form in the lung and contribute to the pathogenesis of this disease. Using an established mouse model of TRALI, Caudrillier and coworkers show that platelet sequestration increases with NET proximity and that aspirin treatment decreases NET formation and NET-associated platelets. Moreover, human platelets activated with the PAR-1 agonist, thrombin receptor-activating peptide (TRAP), induced robust NET release via Thromboxane A2. Further investigation into how platelets drive NETosis revealed dependence on the canonical Raf/MEK/ERK signaling pathway that is also critical to PMA-induced NADPH-dependent NETosis. Despite the reported association of NETs with TRALI, a different study by Thomas and colleagues found that platelet depletion did not completely abrogate NETosis and that FcγR engagement by anti-neutrophil antibodies was sufficient to promote NET release. Moreover, this study showed that DNase administration effectively prevented NET-mediated ALI only when delivered through inhalation, probably because of the predominant accumulation of NETs within alveolar spaces. NET inhibition rather than digestion also appears to be a promising approach to preventing TRALI as indicated by a recent study where the administration of Disulfiram, an FDA-approved gasdermin D inhibitor for the treatment of alcohol abuse, prevented signs of lung injury.

21In summary, NETs appear to have a pathogenic role in TRALI, and preclinical observations indicate that NET inhibition or digestion may improve TRALI outcomes. However, conflicting reports as to the specific contribution of platelet activation to NET-mediated tissue injury in TRALI further highlight the need for studies to dissect the molecular mechanisms of NETosis in vivo.

22LIRI is a primarily sterile inflammatory disease occurring in lungs that sustain ischemic damage followed by reperfusion. LIRI is typically associated with pulmonary embolisms and various cardiothoracic surgical procedures, including lung transplantation (LTx). The physiopathological mechanisms of LIRI are incredibly complex, and the specific contribution of neutrophils is still debated. The prevailing view is that LIRI is a bimodal process, with an early phase primarily dependent on pulmonary macrophages and activated platelets followed by later neutrophil-mediated damage.

23A recent study by Sayah and colleagues demonstrated a pathogenic role for NETs in primary graft dysfunction (PGD), a common form of LTx-related LIRI occurring within 72 hours. after surgery. Using a mouse model of syngeneic orthotopic left lung transplant (OLT), this group detected the presence of intra-graft NETs in association with platelet activation. Pretreatment with aspirin or intrabronchial administration of DNase were both able to attenuate signs of PGD in the OLT model. A later study by our group extended these findings by visualizing intragraft NETosis by intravital 2-photon microscopy in an allogeneic mouse model of OLT. Interestingly, the systemic administration of DNase improved lung function but at the cost of increasing alloimmune responses and graft rejection due to the release of inflammatory NET fragments. However, directly targeting NET generation by the genetic deletion or pharmacological inhibition of PAD4 prevented alloimmune responses and allograft rejection. The unintended consequences associated with NET digestion have been increasingly described in different animal models, raising the question of whether it is more effective to prevent NETosis in lieu of DNase treatment. For example, NETs have been described to merge in high-density structures named aggNETs, which are thought to prevent bystander tissue injury as well as contribute to wound healing and inflammation resolution through driving the proteolytic degradation of cytokines and histones. Most recently, our group has provided further insight into the mechanisms of NET-mediated graft injury by showing that necroptosis, occurring in response to warm-ischemia, drives early neutrophil accumulation into the sub-pleural capillary network resulting in NET-mediated microvascular damage. Necroptosis is a Receptor Interacting Serine/Threonine Kinase 3 activation-mediated form of cell death that leads to the extracellular release of various alarmins, including mitochondrial-derived DAMPs (mtDAMPs). Additionally, our group and others have shown that LIRI leads to the release of mtDAMPs, which guide neutrophil intragraft trafficking, stimulate ROS production and trigger NETosis.

24Altogether, the observations from the LIRI models and human LTx recipients with PGD support the notion that DAMPs released from the ischemic tissues induce innate immune responses resulting in NETosis and tissue injury. Interfering with the mechanisms that activate NETosis rather than enhancing the degradation of NETs appears a more desirable option for attenuating LTx-related ALI without increasing the risk of allograft rejection.

25VILI is a form of ALI triggered by mechanical ventilation. Neutrophil recruitment in response to VILI is driven by L-selectin expression and is promoted by stretch-induced inflammatory events that lead to the release of neutrophil chemokines such as CXCL1 (KC) and CXCL2/3 (MIP-2). Short periods of mechanical ventilation have been shown to be associated with the release of pro-inflammatory cytokines, including TNF-α, IL-1β and IL-8, which are well-known activators of NETosis. Accordingly, recent studies have focused on the possible contribution of NETs to VILI pathogenesis. Using a “double-hit” model of intra-tracheal LPS challenge followed by high tidal mechanical ventilation, Yildiz and colleagues showed that VILI is associated with significant NET release. DNase, also administrated intratracheally, reduced BAL markers of NETs and improved lung compliance but did not affect other measures of lung injury including oxygenation, inflammatory cell infiltration and lung permeability. The singular improvement in lung compliance led the authors to hypothesize that DNase treatment decreased airway secretion viscosity rather than imparting VILI protection. In contrast to these findings, Rossaint and coworkers found that targeting NETs with DNase effectively protected mice from ALI in a single hit model of VILI. Moreover, the group further demonstrated that VILI-induced NETosis is a platelet-dependent process requiring simultaneous stimulation of integrins and G-protein–coupled receptors on neutrophils. Using the same single hit model of VILI, Li and coworkers confirmed the beneficial effect of DNase treatment in preventing ALI and showed that TLR4 signaling is implicated in the release of NETs in VILI.

26In summary, the current evidence shows that NETs are released during VILI and that targeting NETs may be beneficial in preventing injury in this setting. The differing effects observed with DNase treatment may be related to the use of alternative experimental models suggesting further pre-clinical evaluation is likely necessary to better characterize the effects of NETosis on VILI.

27Trauma is defined as an injury caused by an external physical force, as it may result in the consequence of blunt force impact, penetrating injuries, or extensive thermal and chemical burns. Although advancements in surgery and resuscitation have substantially increased the chance of surviving a major trauma, some patients still develop systemic inflammatory response syndrome (SIRS) and infections. ARDS is a well-known complication of major trauma, and it represents one of its leading causes of death. Trauma is commonly associated with the loss of natural barrier function, which places large demands on neutrophils to scavenge tissue debris and control the diffusion of pathogens. However, due to the large microvascular bed and the long transit time, the lung represents a preferred site for the accumulation of activated neutrophils after trauma. NET release has been demonstrated in several experimental models of trauma, and elevated levels of circulating NET markers have been associated with the worst clinical outcomes in subjects developing trauma-related ARDS. Interestingly, ARDS resulting from trauma seems to be overall associated with better clinical outcomes when compared to other forms of ARDS, suggesting the presence of peculiar immunological features. In this regard, trauma is a known driver of emergency hematopoiesis leading to a high number of circulating immature neutrophils with impaired effector functions. In addition, trauma induces the expansion of specific neutrophil subsets that are either unresponsive or display immunosuppressive activity, increasing the risk of secondary infections. Recent work by Hazeldine and colleagues has suggested that reduced neutrophil activity in the trauma setting is related to their ability to form NETs. This group demonstrated that a few minutes after the injury, neutrophils exhibit an activated phenotype characterized by enhanced glucose metabolism and NETosis. However, hours later, neutrophils became unresponsive, and their ability to form NETs dramatically decreased. To explain this apparent change in neutrophil function, the authors hypothesize that mtDAMPs, such as N-formylated peptides, desensitize neutrophils to further stimulation, effectively reducing their ability to release NETs. Recent findings from Itagaki and colleagues support the existence of this regulatory pathway. They showed that blocking the N-formylated peptide receptor-1 (FPR1) preserves neutrophil function after trauma. Other evidence, however, point to the pro-inflammatory role of mtDAMPs in activating neutrophils, increasing NETosis, and predisposing to the development of SIRS. Further complicating this picture, studies of trauma subjects show reduced endogenous DNase activity and increased circulating cell-free DNA levels associated with post-injury complications. Despite the general state of immune unresponsiveness and the increased risk of infection, these studies suggest that restoring DNase activity is likely beneficial after trauma.

28In summary, ALI associated with trauma appears to display peculiar immunological features, possibly related to the sudden and massive release of DAMPs and the alteration of regulatory mechanisms that promote DAMP clearance. How different DAMPs control neutrophil metabolism, differentiation and NETosis as well as shape host responses to trauma remains to be determined.

29Increasing evidence suggests that NETs play an essential role in infectious and sterile ALI and that circulating NET markers can predict worst clinical outcomes in ARDS subjects. Most of the current literature has focused on the use of DNase in preventing NET-mediated ALI. However, although DNase has shown promising results in reducing signs of lung injury and inflammation associated with NET release, several questions about its global use to treat ARDS conditions remain. For example, does DNase-mediated NET degradation increase the risk of infection? In addition, do the rapid release of histones and proteases following DNAse treatment have unintended effects on outcomes? Preventing formation rather than digesting NETs may offer a more suitable alternative strategy to treat some forms of ALI. In this regard, selective inhibitors have been developed to prevent the generation and release of NETs at different stages of NETosis. Nevertheless, it remains to be determined if NET formation inhibitors will be effective for most forms of ALI and, like DNase, could potentially dysregulate host defense. It also remains to be determined if NET inhibitors will be effective for all forms of NETosis, given the apparent redundancy in the pathways that generate NETs. Platelet activation and coagulation factors appear to be highly interconnected with NET release leading to a state of thromboinflammation. Although this mechanism appears to be extremely relevant in the ARDS associated with COVID-19, its contribution still needs to be precisely characterized for other ALI etiologies. In addition, the molecular details that control the crosstalk between innate immunity and coagulation remain poorly understood. DAMPs, particularly those derived from mitochondria, appear to be strongly involved in the activation of NETosis. Interfering with their signals may represent a promising strategy to reduce exuberant NET release and prevent neutrophil desensitization to microbial PAMPs. However, to safely leverage these observations, pathways that control the delicate balance between neutrophil activation and desensitization will need further investigation.

30In conclusion, future studies that better define the mechanisms involved in the formation, release, and degradation of NETs could form the basis of therapeutic strategies that target ALI without disabling pathogen surveillance.

31DS, FL, AK, DK, and AG contributed to conception and design of the study. DS wrote the first draft of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

32This study was funded by the NIH (NIH R01HL094601, NIH P01AI11650, NIH R01HL157407).

33The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

34All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.